The FDA has extended the review period of the New Drug Application (NDA) for baricitinib, Eli Lilly/Incyte Corporation’s once-daily investigational oral rheumatoid arthritis (RA) treatment, an additional 3 months beyond the Prescription Drug User Fee Act’s 1-year goal for reviewing NDAs. The additional time was needed to review more data submitted by Lilly in response to information requests made by the agency.
Some analysts considered baricitinib a potential “blockbuster” because it has shown clinical superiority over Humira (adalimumab), has a strong safety profile, and is an oral, rather than injection, RA treatment that was expected to be close to launch and possibly available before Humira biosimilars enter the market.
The NDA for baricitinib was submitted to the agency for review in January 2016. However, the FDA determined that submission of additional information constituted a Major Amendment to the NDA, resulting in the 3-month extension. Baricitinib was also submitted for regulatory review in the European Union and Japan in early 2016. The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use issued a positive opinion of the drug in December 2016, recommending its approval. If approved in Europe, it would be marketed there as Olumiant. The drug is also being studied in phase II trials for atopic dermatitis and systemic lupus erythematosus, and a phase III trial for patients with psoriatic arthritis is expected to begin in 2017.
Baricitinib is an oral JAK (Janus kinase) inhibitor in development for inflammatory and autoimmune diseases. There are four known JAK enzymes, and JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a range of inflammatory conditions, according to Lilly. “We will continue to work closely with the FDA throughout the review process and we believe that baricitinib has the potential to be an effective treatment choice, especially for those patients for whom current therapies are not adequately addressing their disease,” said J. Anthony Ware, MD, senior vice president, product development, and interim president of Lilly Bio-Medicines.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.